Physicians cover the options for a patient with hormone receptor–positive, HER2-negative, early-stage breast cancer, which course of action they would take, and the data supporting that choice.
CDK Inhibition in HR-Positive, HER2-Negative Early-Stage Breast Cancer
Manali Bhave, MD, discusses the updated results of the MonarchE study of abemaciclib in patients with hormone receptor-positive, HER2-negative, breast cancer.
During a live virtual event, Lowell Hart, MD, discussed the findings of the monarchE trial of abemaciclib in high-risk patients with early breast cancer.
During a live virtual event, Lowell Hart, MD, discussed the results of the monarchE trial of abemaciclib in patients with node-positive, hormone receptor–positive, HER2-negative, high-risk early breast cancer.